Ibrutinib resistance mutations often arise early, suggesting potential as a cue for alternative therapy

[AussieNeil]

Mutations in two genes often occurred months before relapse of chronic lymphocytic leukemia (CLL) treated with ibrutinib (Imbruvica), suggesting potential as a cue for alternative therapy, according to a retrospective review of four clinical trials.

Among patients who had CLL relapse, acquired mutations in BTK and PLCG2 occurred in 85% of cases. The mutations arose a median of 9.3 months prior to overt disease relapse, reported Jennifer A. Woyach, MD, of Ohio State University in Columbus, and colleagues.

medpagetoday.com/Hematology...

Neil

Photo: Seal Pup at Seal Bay, Kangaroo Island

[newyork8]

Even if the mutations are found early are there other treatments besides the ones we know about to deal with this? Isn't it still a choice of fcr br or idela or obin or venetoclax? Do we know which of these address certain mutations better than others?

[Cllcanada Top Poster CURE Hero in reply to newyork8]

No ... very early days on these mutations... still in the lab...

Still trying to expand the knowledge base...

~chris

[db601]

Great photo - pure eye candy - thank your!

[AussieNeil Partner Administrator]

I see I've doubled up on an earlier posting by Cllcanada that can be found here: healthunlocked.com/cllsuppo...

[Hoffy]

Thank you for a good article. I was treatment naïve now On imbruvica and will add Veneticlax soon but 17 P deleted so I will need to watch for this. I am on a clinical trial. Hopefully the combo therapy will knock down the disease so much that this will not be in issue.

It is good to know it can be seen early.